“Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” said James Nathanielsz, CEO of Propanc. “We are focused on initiating the Phase 1b PRP clinical trial, advancing Rec-PRP into preclinical development, and expanding our IP portfolio. With our recent Nasdaq uplisting and long-term financing facility, we are well-positioned to accelerate commercialization of our proenzyme technology.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPCB:
- Propanc Biopharma Secures $1M Through Stock Sale
- Propanc Biopharma enters securities purchase agreement with Hexstone
- Propanc Biopharma announces initiative to pursue acquisition of DAT
- Propanc Biopharma announces financing agreement up to $100M
- Propanc Biopharma Enters Securities Purchase Agreement